Results 241 to 250 of about 10,843,123 (260)

Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies

Journal of Alzheimer's Disease, 2018
Background: Amyloid-related imaging abnormalities with effusion or edema (ARIA-E) reported in patients with mild-to-moderate Alzheimer’s disease in bapineuzumab phase III studies. Objectives: Assess symptoms, clinical severity, and ARIA-E outcomes, and to evaluate effects on cognition and function.
H Robert, Brashear, Nzeera, Ketter, Jennifer, Bogert, Jianing, Di, Stephen P, Salloway, Reisa, Sperling   +5 more
openaire   +2 more sources

Refractory Status Epilepticus in a Patient With Aducanumab-Induced Amyloid-Related Imaging Abnormalities

Neurology
To report a case of fatal super-refractory status epilepticus associated with amyloid-related imaging abnormalities (ARIA).We describe the history, neuroimaging, EEG, and brain pathology findings of a 75-year-old patient with mild cognitive impairment due to Alzheimer disease (homozygous ε4 apolipoprotein status) and a remote history of 3 asymptomatic ...
Joel Neves Briard, Antoine Duquette, Romain Cayrol, Samuel Lapalme-Remis   +3 more
openaire   +2 more sources

Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab

JAMA Neurology, 2022
Jacob N, Hall, Elizabeth, Mormino, Amanda, Ng, Athanasia, Boumis, Jennifer L, Gaudioso, Guido A, Davidzon, Sharon J, Sha   +6 more
openaire   +2 more sources

Amyloid-related imaging abnormalities (ARIA)

2022
openaire   +1 more source

MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill?

American Journal of Neuroradiology, 2022
P.F. Høilund-Carlsen, A. Alavi, G. Perry, J.R. Barrio   +3 more
openaire   +2 more sources

Amyloid-related imaging abnormalities during aducanumab for AD

Reactions Weekly, 2021
openaire   +1 more source

Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid

journal of prevention of Alzheimer's disease, The, 2022
Roy Yaari, R Yaari, J R Sims
exaly  

Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy

journal of prevention of Alzheimer's disease, The, 2022
Jérôme Barakos
exaly  

Amyloid-Related Imaging Abnormalities (ARIA): essential insights for diagnosis and management

Learning objectives: 1. Explain the pathophysiology of ARIA in the context of Alzheimer’s disease and provide a brief overview of monoclonal antibodies used in its treatment. 2.
openaire   +1 more source

[Radiological Identification and Evaluation of Amyloid-Related Imaging Abnormalities in Alzheimer's Disease].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
Amyloid-related imaging abnormalities (ARIA), intracranial signal abnormalities observed in magnetic resonance imaging (MRI), represent one of the main adverse events associated with treating Alzheimer's disease (AD) with anti-amyloid-β (anti-Aβ) monoclonal antibodies. In severe cases, patients' lives may be threatened.
Xiyue, Yang, Wanting, Li, Xinglong, Yang, Qin, Chen, Hongxia, Li, Su, Lyu, Na, Hu   +6 more
openaire   +1 more source